LSX World Congress Plenary Panel – Biotech in 2022: Another wave or low tide?
McKinsey’s Alexandra Zemp and Rachel Moss presented intriguing data and provided timely insights on where they see the markets, currently in turmoil, may go in 2022. The McKinsey partners opened with frightening stats that the biotech public markets have declined 36% since 1 Sept 2021 to May 2022. The IPO window has narrowed significantly, with […]